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Human immunodeficiency virus type-1 (HIV-1) infection dramatically increases the risk of development of Kaposi’s
sarcoma (KS) in individuals infected with Kaposi’s sarcoma-associated herpesvirus (KSHV). In a primary effusion lymphoma
(PEL) tissue culture model system, HIV-1 replication potently induced the lytic replication of KSHV and led to the secretion
of soluble factors capable of inducing lytic KSHV replication in bystander cells. Here we demonstrate that HIV induces KSHV
lytic replication through activation of the KSHV Rta. HIV gene expression activated the KSHV Rta promoter following viral
infection or after transfection of proviral DNA. Although HIV-1 Tat has previously been implicated as an activator of KSHV lytic
replication, Tat alone was unable to activate lytic replication and failed to activate the Rta promoter. We conclude that HIV
activates KSHV lytic replication by inducing the KSHV Rta promoter and that factors other than HIV-1 Tat are required toINTRODUCTION
Kaposi’s sarcoma (KS) is the most common neoplasm
observed in individuals infected with the human immu-
nodeficiency virus type 1 (HIV-1). KS occurs 20,000 times
more frequently in HIV-1-infected individuals than in the
general population (Safai et al., 1985; Sturzl et al., 2001).
Kaposi’s sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV-8), is associated
with AIDS-related KS as well as with classical, endemic,
and transplant-associated KS (Boshoff and Weiss, 2001).
KSHV is strongly implicated as a causal agent of KS by
epidemiologic studies and by the presence of KSHV in
essentially all KS tumor tissues (reviewed in Boshoff and
Weiss, 2001). KSHV belongs to the subfamily of gamma
(lymphotropic) herpesviruses, together with Herpesvirus
saimiri, Epstein–Barr virus, and murine gammaherpesvi-
rus 68. Consistent with its classification as a lympho-
tropic herpesvirus, KSHV is found in CD19 B cells in the
lymph nodes and peripheral blood of KS patients (Am-
broziak et al., 1995; Whitby et al., 1995). KSHV is also
associated with two diseases involving lymphoprolifera-
tion: multicentric Castleman’s disease and primary effu-
sion lymphoma (PEL, also known as body cavity-based
lymphoma). In KS tumors, however, KSHV is found in
spindle cells that are predominantly of endothelial origin
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270(Boshoff et al., 1995; Staskus et al., 1997). KSHV in most
KS spindle cells exists in the latent phase of replication,
with a minority of cells demonstrating markers of active,
lytic viral replication (Staskus et al., 1997). KSHV is also
found in circulating cells of monocyte/macrophage lin-
eage and in monocytes within KS lesions (Blasig et al.,
1997; Monini et al., 1999).
The activation of KSHV from latency to lytic replication
is likely to play an important role in the spread of KSHV
within infected individuals and in the pathogenesis of KS.
Active viral replication from lymphoid cells or monocytes
must occur to infect endothelial targets and generate the
KSHV-infected spindle cells that form a major part of KS
tumors. Several lytic cycle gene products of KSHV (such
as viral macrophage inflammatory protein II and viral G
protein coupled receptor) are known to promote neoan-
giogenesis (Arvanitakis et al., 1997; Bais et al., 1998;
Boshoff et al., 1997) and could play a role in the marked
angiogenesis found in KS tumors. A role for lytic replica-
tion in the development of KS is supported by the finding
that KSHV viral load in peripheral blood mononuclear
cells increases as individuals progress from asymptom-
atic infection to clinical KS (Ambroziak et al., 1995; Whitby
et al., 1995). Factors that contribute locally to KSHV lytic
reactivation therefore may serve as significant cofactors
in the development of KS tumors.
We have previously reported that HIV directly stimu-
lates KSHV lytic replication in a PEL-based tissue culture
model system (Varthakavi et al., 1999). HIV infection ofmediate this effect. © 2002 Elsevier Science (USA)
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BC-3 cells harboring KSHV in latent phase produced a
potent activation to lytic phase replication and led to thesi’s sar
release of infectious KSHV in the supernatant. This effect
was blocked by the addition of antiretroviral drugs. The
switch to lytic replication occurred in cells coinfected
with both HIV and KSHV and was also seen in HIV-
uninfected PEL cells through the action of a soluble
mediator of lytic replication. From this data, we proposed
that HIV contributes to the development of KS through its
role in promoting immunodeficiency and in a more direct
manner through promoting KSHV lytic replication. This
idea is supported by reports that antiretroviral therapy
results in a reduction of KSHV viral load and leads to
rapid regression of KS tumors (Lebbe et al., 1998; Wit et
al., 1998).
The molecular switch that controls the transition from
KSHV latency to lytic replication is the product of the ORF
50 gene, designated KSHV Rta (replication and transcrip-
tion activator) (Gradoville et al., 2000; Lukac et al., 1999;
Sun et al., 1998). KSHV Rta is an immediate-early KSHV
gene product whose expression is detected prior to that
of early lytic gene products. Rta expression in BC-1 or
BCBL-1 PEL cell lines results in activation of expression
of early lytic cycle genes such as the polyadenylated
nuclear RNA (PAN), viral interleukin 6 (vIL-6), K8, and ORF
59, as well as activation of late lytic genes (Lukac et al.,
1999; Sun et al., 1998). The role of KSHV Rta as a switch
controlling the transition from latency to lytic replication
was further established by experiments in which a trun-
cated Rta functioned in a dominant-negative manner,
inhibiting spontaneous reactivation from latency and
suppressing viral replication (Lukac et al., 1999).
We hypothesized that HIV stimulates KSHV replication
through activation of the KSHV ORF 50 gene, resulting in
the production of KSHV Rta and leading to the orderly
cascade of gene expression characteristic of KSHV lytic
replication. Using the HIV-infected BC-3 cell model, we
found that HIV potently induced ORF 50 transcription.
Transcription of ORF 50 was followed by the sequential
appearance of lytic transcripts similar to that seen fol-
lowing TPA induction. HIV was shown to activate the Rta
promoter, while Tat alone failed to activate this promoter
and did not induce lytic replication in PEL cells. These
results provide evidence that HIV can activate lytic KSHV
replication through induction of the KSHV ORF50 gene
and provide a basis for the further dissection of the HIV
genes and cellular factors responsible for this effect.
RESULTS
Northern blot analysis of KSHV Rta and lytic gene
products
KSHV ORF 50 encodes a protein termed KSHV Rta that
acts as a molecular switch controlling the transition from
latency to lytic replication (Lukac et al., 1999; Sun et al.,
1998). KSHV Rta has been shown to be both necessary
and sufficient to activate the expression of the viral lytic
genes. We had previously observed that HIV replication
in a PEL cell line activated KSHV lytic replication in a
manner similar to that of phorbol ester treatment
(Varthakavi et al., 1999). We sought to test the hypothesis
that HIV induces KSHV lytic replication by activating
transcription of the ORF 50 gene product. BC-3 cells
were infected with VSV-G-pseudotyped HIV, and polyad-
enylated RNA was harvested from a fraction of the cells
at time 0, 4, 8, 12, and 24 h postinfection. For comparison,
BC-3 cells were treated with 20 ng/ml TPA, and RNA was
harvested in an identical manner. Northern blot analysis
was performed to detect the transcripts of the ORF 50
(Rta) gene product. ORF 50 transcripts were detected at
the 8-h time point following HIV infection and increased
steadily up to 24 h (Fig. 1A). In comparison, TPA treat-
ment resulted in the appearance of ORF 50 transcripts by
the 4-h time point (Fig. 1B). PAN RNA is an abundant
KSHV transcript that arises with early kinetics in re-
sponse to the action of KSHV Rta. As expected, PAN RNA
was detected in a delayed fashion relative to ORF 50
following HIV infection, with the first detectable tran-
scripts seen 12 h after infection. vIL-6 is an early lytic
FIG. 1. Induction of ORF 50 and subsequent lytic transcripts by HIV.
Polyadenylated RNA was prepared from HIV-infected (left panels) or
TPA-treated (right panels) BC-3 cells. Northern blot analysis was per-
formed using radiolabeled probes specific for ORF 50, PAN, vIL-6, or
GAPDH transcripts as indicated. The time of cell harvest is indicated at
the top of each blot, expressed as hours posttreatment or postinfection.
Size markers derived from the formaldehyde-agarose gels prior to
transfer are indicated at the left side of the blots.
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cycle gene that was not detected until 24 h after HIV
infection, while vIL-6 transcripts were detected 12 h after
treatment with TPA. These results demonstrate that
KSHV Rta transcripts arise first following HIV infection,
prior to the appearance of KSHV early gene transcripts,
and strongly suggest that HIV stimulates KSHV lytic rep-
lication through induction of Rta. Subsequent events in
KSHV lytic replication follow in an orderly manner, al-
though with slightly delayed kinetics relative to TPA treat-
ment.
HIV activates the ORF 50 promoter
The transcriptional control elements of the ORF 50
promoter have not yet been precisely mapped. The plas-
mid pRpluc contains 3-kb DNA sequence upstream of
the ORF 50 translation initiation codon and has been
shown to be responsive to TPA and sodium butyrate
(Deng et al., 2000). We utilized pRpluc to determine
whether HIV activates transcription from the ORF 50
promoter. The effects of HIV gene expression on the ORF
50 promoter were first assessed in human embryonic
kidney 293 cells. Transfection of the backbone vector
(pGL2basic) resulted in little detectable luminescence,
and treatment of cells with TPA had no effect on this
background level (Fig. 2A, columns 1 and 2). Transfection
of the ORF 50 promoter-luciferase construct pRpluc re-
vealed a basal level of expression from this promoter
construct that was 10-fold greater than the empty vector
(column 3). All further results reported as fold induction
of the reporter were calculated with reference to this
basal level of expression from pRpluc. TPA treatment of
293 cells transfected with pRpluc led to an induction of
10.7-fold over expression in untreated cells (Fig. 2A,
column 4), confirming the TPA-responsive nature of the
ORF 50 promoter. Cotransfection of HIV-1 proviral DNA
resulted in activation of the ORF 50 promoter at a level
greater than that of TPA (20.7-fold, column 5). These
results established that HIV-specific gene expression
potently activates the ORF 50 promoter.
HIV-1 Tat is a promiscuous transactivator of viral and
cellular promoters and has been implicated as a trans-
activator of KSHV lytic replication (Harrington et al.,
1997). We next performed experiments designed to es-
tablish the role of Tat in the activation of the ORF 50
promoter. Transfection of HIV-1 proviral DNA containing
a termination codon in place of the tat ATG (pMtat()
(Sadaie et al., 1988) did not significantly enhance ORF 50
promoter activation (Fig. 2A, column 6). Complementa-
tion of this tat provirus by cotransfection of a Tat ex-
pression plasmid enhanced activation of the ORF 50
promoter (10.9-fold, column 7). Tat expression alone ac-
tivated the ORF 50 promoter only very weakly (column 8).
Taken together, these results indicate that HIV gene
expression activates the ORF 50 promoter, while HIV-1
Tat itself is not sufficient to activate the ORF 50 promoter.
The increase in promoter activation seen with the tat-
deficient provirus upon coexpression of Tat indicates
that Tat-dependent HIV gene expression plays a role in
ORF 50 induction.
Our results demonstrating a lack of activity of Tat upon
FIG. 2. Activation of the ORF 50 promoter in 293 cells. (A) Lumines-
cence originating from the pGL2basic or pRpluc reporter plasmids is
shown. Combinations of plasmids and TPA treatment employed in each
experimental arm are indicated in the table beneath the corresponding
bar graph. All DNA transfections were normalized to 10.1 g using
empty vector DNA. Results shown are corrected for transfection effi-
ciency and represent the mean and standard deviation from experi-
ments performed in triplicate. Fold induction relative to pRpluc alone
(column 3) is shown above each bar. (B) Tat activity in transfected cells
was determined by a -galactosidase reporter activity from plasmid
pHIVLTRlacZ via spectrophotometry using a kinetic readout. Results
shown represent means and standard deviation from the same exper-
iment shown in A.
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the ORF 50 promoter and strong activity of intact proviral
gene expression could potentially be explained by differ-
ential expression levels of Tat produced by provirus vs
the Tat-expression plasmid pSVtat72. To determine
whether this was the case, each of the relevant experi-
ments presented in Fig. 2A also incorporated an HIV-LTR
reporter control (pHIVLTRlacZ). This HIV-LTR -galacto-
sidase reporter construct is a sensitive indicator of Tat
activity (Maio and Brown, 1988). The level of Tat activity
as measured by HIV-LTR reporter induction was greatest
for the cells cotransfected with pSVtat72 (36.9-fold, Fig.
2B, column 5), while Tat activity in cells transfected with
intact provirus was less but still quite significant (26.3-
fold activation, column 2). Cells transfected with tat-
deficient provirus (pMtat()) demonstrated minimal acti-
vation of the HIV-LTR (column 3), while cotransfection of
pSVtat72 and pMtat() led to levels of Tat activity com-
parable to provirus (24.1-fold, column 4). These results
establish that the enhanced activation of the ORF 50
promoter by HIV expression in 293 cells is not due to
greater levels of Tat expression and support the hypoth-
esis that Tat-mediated HIV gene expression is neces-
sary, but Tat itself is not sufficient, for HIV-mediated
stimulation of the KSHV ORF 50 promoter.
We next examined ORF 50 promoter activity in BC-3
cells. BC-3 cells harbor KSHV in latent phase replication
and were chosen for these experiments because of their
utility in studying HIV-KSHV interactions in an estab-
lished tissue culture model system (Varthakavi et al.,
1999). Transfection of PEL cells is in general much less
efficient than 293 cells, but levels of transfection of
5–10% were achieved in these experiments using lipo-
some-mediated transfection (data not shown). Back-
ground luminescence was similar with the backbone
vector and pRPluc in BC-3 cells, while TPA generated a
9.8-fold increase in ORF 50 reporter expression (Fig. 3A,
columns 1, 3, and 4). We then infected BC-3 cells with
VSV-G-pseudotyped HIV following transfection with the
reporter construct. HIV-infected BC-3 cells demonstrated
a 12.4-fold activation of the ORF 50 promoter (column 5).
Next, we generated tat-deficient, VSV-G-pseudotyped
HIV particles from 293T cells cotransfected with
pMtat() and pSVtat72. These viruses are competent for
only a single round of infection, as no Tat will be pro-
duced in the target cell. Infection of BC-3 cells with
tat-deficient HIV led to a 3.1-fold increase in ORF 50
promoter activity (column 6). When Tat was supplied to
BC-3 cells via transfection with pSVtat72 prior to infection
with tat-deficient HIV, ORF 50 activation increased to
6.9-fold (column 7). Expression of Tat in BC-3 cells by
transfection (pSVtat72) or by treatment of cells with sol-
uble, recombinant Tat protein produced a small but re-
producible activation over baseline levels (1.9- and 1.5-
fold induction, respectively). The relative amount of Tat
produced in the experiments presented in Fig. 3A was
determined using an HIV-LTRlacZ reporter as described
above. The amount of Tat in cells infected by
pseudotyped HIV was sufficient to activate the LTR re-
porter (11.6-fold), but total Tat activity was less in these
cells than in cells transfected with pSVtat72 (Fig. 3B).
Cumulatively, the results of these studies in BC-3 cells
support the finding in 293 cells that HIV gene expression,
FIG. 3. Activation of the ORF 50 promoter in BC-3 cells. (A) Lumines-
cence originating from the pGL2basic or pRpluc reporter plasmids is
shown. The plasmids, protein treatments, or infections employed are
indicated in the table beneath the corresponding bar graph. Transfec-
tions were performed as described in the legend to Fig. 2. Fold induc-
tion relative to pRpluc alone (column 3) is shown above each bar. (B)
Tat activity in transfected cells was measured as described in the
legend to Fig. 2.
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and not Tat alone, is responsible for ORF 50 promoter
activation. In addition, the effect of HIV infection (rather
than transfection) on ORF 50 promoter activation is di-
rectly demonstrated by the results shown in Fig. 3A.
Tat is not sufficient to mediate KSHV lytic protein
induction
The ORF 50 promoter reporter studies described
above strongly suggested that HIV gene expression, but
not Tat alone, could induce the switch from latent to lytic
cycle replication. To support this hypothesis, we next
examined the expression of lytic KSHV proteins in re-
sponse to either HIV infection or to exposure to HIV-1 Tat
protein. The ORF 59 gene product is a 50-kDa lytic cycle
protein that is involved in viral DNA replication and has
been widely utilized as a marker of lytic KSHV replication
(Chan et al., 1998). When BC-3 cells were infected with
HIV, lytic replication was induced as indicated by this
marker (Fig. 4A, lane 3). Similarly, lytic replication was
induced following transfection of cells with wild-type
HIV-1 proviral DNA (Fig. 4A, lane 4). However, no induc-
tion of ORF 59 expression was seen following transfec-
tion with a tat-deficient provirus unless tat was ex-
pressed in trans (Fig. 4A, lanes 5 and 6). Remarkably,
provision of recombinant Tat protein (lane 7) or expres-
sion of Tat via transfection (lane 10) led to no induction of
lytic protein expression. Control transfected cells and
cells exposed to a control protein also failed to demon-
strate ORF 59 induction (lanes 8 and 9). The results of
ORF 59 immunoprecipitation presented in Fig. 4 are
representative of those from three separate experiments.
The activity of Tat in the experimental arms presented
in Fig. 4A was measured using an HIV-LTR luciferase
reporter gene assay. Induction of the HIV-LTR above
background levels was detected with each of the treat-
ments in which Tat was provided, in the form of trans-
fection with a Tat-expression plasmid or as recombinant
protein (Fig. 4B). Of note, the highest level of Tat activity
in this experiment was seen in cells transfected with
pSVtat72 alone (Fig. 4B, far right bar). The HIV-LTR lucif-
erase reporter construct demonstrated slightly higher
background reporter activity in BC-3 cells than did the
pHIV LTRlacZ vector utilized in our previous experiments
(Fig. 4B, LTR-luc). The lack of lytic gene product detected
from cells transfected by this vector alone, together with
the presence of lytic gene product when the vector was
cotransfected with a tat-deficient provirus, strongly sup-
ports the idea that tat-dependent HIV gene transcription
is required for HIV-mediated induction of KSHV lytic rep-
lication. Clearly, however, Tat alone is insufficient.
The soluble factor responsible for KSHV lytic
induction is not Tat
HIV induces KSHV lytic replication in cells coinfected
with both viruses. In addition, a soluble factor released
from HIV-infected BC-3 cells induces KSHV lytic replica-
tion in HIV-uninfected PEL cells (Varthakavi et al., 1999).
The nature of this soluble lytic mediator is not yet known.
Tat is released from HIV-infected cells and can enter
HIV-uninfected cells. Thus, Tat is a candidate lytic induc-
tive factor present in HIV-infected BC-3 cell superna-
tants. To determine whether soluble Tat activates lytic
KSHV replication, we compared the activity of the soluble
factor present in HIV-infected BC-3 supernatants to that
of recombinant Tat protein. The recombinant Tat protein
FIG. 4. Lytic protein induction by HIV gene expression vs HIV Tat. (A)
BC-3 cells were subjected to the following treatments: no treatment,
lane 1; 20 ng/ml TPA, lane 2; infection with HIV-1NL4-3, lane 3; transfec-
tion with pNL4-3, lane 4; transfection with pMtat(), lane 5; cotrans-
fection with pMtat() and pSVtat72, lane 6; addition of 10 g/ml
recombinant Tat protein, lane 7; addition of 10 g/ml recombinant HIV
matrix protein as negative control, lane 8; transfection with pHIVLTRluc
alone, lane 9; transfection with pSVtat72 alone, lane 10. Cotransfection
of pHIVLTRluc was carried out in each experimental arm except for the
untreated and TPA-treated arms (lanes 1 and 2). Radiolabeled BC-3
cells were harvested at 48 h posttreatment and immunoprecipitation
analysis performed for the ORF 59 lytic gene product. Molecular mass
markers are indicated on the left in kilodaltons. (B) Tat activity was
monitored in BC-3 cells using luciferase counts generated from pHIV-
LTRluc. The intervention employed in each experimental arm is indi-
cated below the bar graph. Note the break in the pSVtat72 bar repre-
senting a value beyond the scale shown on the y-axis.
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utilized was active in HIV-LTR reporter assays (data not
shown), indicating that it was biologically active. Infec-
tion of BC-3 cells with pseudotyped HIV resulted in lytic
activation of KSHV in the cell population as detected by
immunofluorescence staining with the ORF 59 monoclo-
nal antibody 11D1 (Fig. 5A). Supernatants harvested from
HIV-infected BC-3 cells were then added to uninfected
BC-3 cells, leading to induction of lytic replication (Fig.
5B). Control supernatants from HIV-uninfected BC-3 cells
did not induce lytic cycle replication (Fig. 5E). We next
asked if the soluble lytic activity required the presence of
HIV or KSHV virions in the supernatants. Viruses were
removed from the supernatants by ultracentrifugation.
p24 analysis of the supernatants following centrifugation
confirmed that detectable virus had been removed by
this treatment (data not shown). Virus-free supernatants
retained the inductive activity seen previously (Fig. 5C).
To determine whether the soluble lytic activity was due to
Tat, we added recombinant Tat (10 g/ml) to the media of
BC-3 cells. No induction of ORF 59 gene expression over
background levels was observed (Fig. 5D). Similarly, su-
pernatants derived from HIV-infected MT-2 cells lacked
any lytic inductive activity (Fig. 5F). These results indicate
that the soluble factor activity detected in HIV-infected
BC-3 supernatants is not due to the released virions
themselves and is not attributable to Tat.
To further define the nature of the soluble factor and to
exclude Tat as a candidate soluble lytic factor, we re-
peated the soluble factor experiments but utilized immu-
noprecipitation analysis as the measured endpoint. In
addition, we directly measured the amount of Tat activity
in each of the treatment arms, using a reporter cell line
with an integrated, tat-deficient provirus. In this assay,
the amount of p24 released following exposure to Tat
correlates with the amount of active Tat present in the
supernatants. A treatment arm in which Tat was immu-
nodepleted from HIV-infected BC-3 supernatants was
included in this analysis. Addition of supernatant from
HIV-infected BC-3 cells led to a significant increase in
ORF 59 expression (Fig. 6A, lane 2). Depletion of viral
particles did not eliminate this lytic activity (lane 3) nor
did immunodepletion of Tat (lane 4) or treatment with an
isotype-matched IgG control antibody (lane 5). No induc-
tion was demonstrated when BC-3 cells were treated
with recombinant Tat protein or control recombinant HIV
matrix protein (lanes 6 and 7, respectively). Tat activity
present in each treatment arm of this experiment is
indicated in Fig. 6B. Biologically active Tat was detected
in each of the HIV-infected BC-3 cell supernatants, with
the exception of the supernatants that had been immu-
nodepleted with an anti-Tat antibody (Fig. 6B). Recombi-
nant Tat protein retained biological activity, although at a
FIG. 5. Immunofluorescence analysis of soluble factor lytic inductive activity. Immunofluorescence was performed on BC-3 cells 48 h following each
indicated intervention, using monoclonal antibody 11D1 for detection of the ORF 59 gene product. (A) Infection with VSV-G-pseudotyped HIV-1NL4-3;
(B) supernatants from HIV-infected BC-3 cells; (C) viral particle-depleted supernatants from HIV-infected BC-3 cells; (D) 10 g/ml recombinant Tat
protein; (E) control BC-3 cell supernatants; (F) HIV-infected MT-2 cell supernatants.
275HIV-MEDIATED ACTIVATION OF KSHV Rta
somewhat lower level than that seen in the HIV-infected
supernatants. These data support previous results indi-
cating that the soluble factor responsible for lytic induc-
tion of KSHV is not HIV-1 Tat.
DISCUSSION
Cofactors that enhance the lytic replication of KSHV
may play an important role in the pathogenesis of KS.
Following exposure to KSHV, lytic replication is required
for the initial spread to target B lymphocytes and mono-
cytes. Additional rounds of productive replication are
required to infect the endothelial cell progenitors that
form the spindle cells that are characteristic components
of a KS tumor. It is likely that higher levels of lytic
replication will alter the balance between clearance of
infected cells by the host immune system and infection
of new cells by virus, favoring the spread of virus to new
tissues. Cofactors present in the microenvironment of
cells infected with KSHV may thus enhance early viral
spread and ultimately enhance pathogenicity. Factors
enhancing lytic replication may also play a role in the
disease process at later time points. At the time that a
tumor is first evident, most spindle cells harbor KSHV in
latent phase replication (Sturzl et al., 1997). However, a
subpopulation of cells undergoing lytic replication are
uniformly present in tumors, and these cells have been
postulated to play a role in the maintenance of the tumor.
Monocytes in KS tumors have been shown to be produc-
tively infected with KSHV (Blasig et al., 1997); these cells
may be an important reservoir of virus and may be
responsible for the high KSHV viral load that is seen in
late stages of KS. The identification of cofactors that
enhance KSHV lytic replication at both early and late time
points following infection is thus an important goal in
understanding KS pathogenesis.
HIV is an important cofactor for the development of KS.
The contribution of HIV to KS pathogenesis is likely to be
multifactorial. Immunosuppression induced by HIV is
likely to play a major role (Jacobson et al., 2000). HIV
alters the immune activation state of the infected host,
leading to the release of inflammatory cytokines that can
have profound effects upon KS tissues (Fiorelli et al.,
1998; Samaniego et al., 1995, 1997). HIV replication re-
sults in the release of HIV-1 Tat, which has been impli-
cated as an autocrine factor in the development and
maintenance of KS tumors (Buonaguro et al., 1992; Ensoli
et al., 1994; Fiorelli et al., 1998). We suggest that in
addition to these proposed mechanisms, HIV may en-
hance KS tumor formation by enhancing the lytic repli-
cation of KSHV through mechanisms that are separate
from the effects of soluble Tat protein.
We have previously established that HIV infection of
cells harboring KSHV in latent-phase replication induces
lytic replication (Varthakavi et al., 1999). In a tissue cul-
ture model, cells infected with both HIV and KSHV were
stimulated to undergo lytic replication, and a soluble
factor was produced that induced KSHV replication in
HIV-uninfected cells. In the current study, we demon-
strate that HIV induces KSHV lytic replication through
stimulating production of the KSHV Rta protein. Produc-
tion of KSHV Rta then triggers the cascade of events
leading to lytic replication that is seen following stimu-
lation with phorbol esters. HIV activates transcription
from the ORF 50 promoter in a manner that is dependent
upon Tat-mediated HIV gene transcription. However, Tat
itself is not sufficient to activate KSHV lytic replication.
FIG. 6. Immunoprecipitation of lytic proteins produced in response to
soluble factor or Tat. Target BC-3 cells were exposed to soluble factor
supernatants derived from HIV-infected BC-3 cells or to the indicated
treatment. Cells were radiolabeled and harvested for immunoprecipi-
tation analysis of the ORF 59 gene product at 48 h following treatment.
(A) BC-3 cells were subjected to no treatment, lane 1; soluble factor
supernatants, lane 2; viral particle-depleted supernatants, lane 3; sol-
uble factor supernatants depleted of Tat using an immunodepletion
strategy, lane 4; mock immunodepletion using an isotype-matched
antibody, lane 5; addition of 10 g/ml recombinant Tat protein, lane 6;
or control recombinant HIV matrix protein, lane 7. (B) Tat activity in each
treatment arm was assessed using p24 production by the CEMtat()
cell line.
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These results establish that additional HIV gene prod-
ucts are required to activate the ORF 50 promoter and
suggest that strategies to map the precise HIV gene
products responsible should be feasible. These studies
are presently in progress. Although it is possible that an
HIV-specific gene product directly activates the ORF 50
promoter, we believe it is more likely that products of HIV
gene transcription alter the intracellular milieu in ways
that induce this promoter. Dissection of the pathway
leading to ORF 50 promoter activation by HIV may reveal
mechanisms that are relevant to additional putative co-
factors for KS development. In this regard, it is interesting
to note that human cytomegalovirus has also been
shown to activate lytic replication of KSHV (Vieira et al.,
2001).
Several soluble factors that lead to lytic KSHV replica-
tion have been described. Mercader and colleagues
described lytic effects from Oncostatin M, hepatocyte
growth factor/scatter factor, and interferon- derived
from HIV-infected T cells in a mixed culture with the
BCBL-1 cell line (Mercader et al., 2000). Harrington and
co-workers implicated soluble HIV-1 Tat as an activator
of KSHV lytic replication (Harrington et al., 1997). Our
group previously reported the presence of a soluble
factor released from HIV-infected PEL cells that potently
activated KSHV lytic replication (Varthakavi et al., 1999).
The current work extends these findings to definitively
show that the soluble inductive factor from HIV-infected
BC-3 cells is not Tat and that Tat itself is not sufficient to
activate lytic replication. This finding is most conclusively
shown by experiments in which Tat was immunode-
pleted from the supernatants without the loss of lytic
inductive activity (Fig. 6). The fact that HIV-infected MT-2
supernatants fail to stimulate lytic replication in our ex-
periments, while HIV-infected BC-3 supernatants are ac-
tive, suggests that KSHV-specific gene products may be
necessary for production of the soluble lytic factor. Ef-
forts to identify the soluble inductive factor present in
HIV-infected PEL supernatants are in progress. We an-
ticipate that identification of this soluble inductive factor
may have implications for KSHV replication in vivo. If HIV
infection in lymphoid tissues releases such a lytic induc-
tive factor, neighboring B cells, monocytes, or endothelial
cells infected with KSHV may be induced to produce
infectious virus.
This study raises the possibility that HIV enhances the
pathogenicity of KSHV by enhancing KSHV replication
when both viruses are present in common tissues. Al-
though cells infected with both HIV and KSHV have not
been identified in KS tissues, the dual infection of indi-
vidual cells of the macrophage/monocyte lineage is a
possibility that has not been excluded. Whether or not
coinfected cells exist, the production of soluble factors
capable of potently inducing KSHV lytic replication is
deserving of further study. Identification of these soluble
factors may lead to novel strategies to inhibit the pro-
ductive replication of KSHV in infected individuals.
MATERIALS AND METHODS
Cell lines
BC-3 cells (CRL-2277) and 293 cells (CRL 1573) were
obtained from the American Type Culture Collection
(ATCC), Manassas, VA. CEMtat() cells (Feinberg et al.,
1991) were a gift from Mark Feinberg obtained through
Chris Aiken. MT-2 cells were obtained from Dr. Douglas
Richman through the NIH AIDS Research and Reference
Reagent Program. BC-3 cells, MT-2 cells, and CEMtat()
cells were maintained in RPMI 1640 (Gibco-BRL, Gaith-
ersburg, MD) supplemented with 10% fetal calf serum
(FCS), 2 mM L-glutamine, 100 U penicillin, and 100 g
streptomycin per milliliter in the presence of 5% CO2. 293
and 293T cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco-BRL) supplemented with
10% FCS and 100 U and 100 g penicillin and strepto-
mycin per milliliter, respectively.
Plasmids
The following plasmids were obtained through the
AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIH: pHIVlacZ (Maio and Brown, 1988) from
Dr. Joseph J. Maio, pSVtat72 (Frankel and Pabo, 1988)
from Dr. Alan Frankel, pNL4-3 (Adachi et al., 1986) from
Dr. Malcolm Martin, pTatC6H-1 (Purvis et al., 1995) from
Dr. Abhay Patki and Dr. Michael Lederman, and pMtat()
(Sadaie et al., 1988) from Dr. Reza Sadaie. pHIVLTRluc
was constructed by inserting a 247-bp HindIII–XhoI frag-
ment from pHIVlacZ into the HindIII–XhoI sites of
pGL2basic (Promega, Madison, WI), placing the lucif-
erase reporter gene under the control of the HIV-LTR
promoter. The Rta promoter-reporter plasmid pRpluc
contains a 3-kb DNA fragment immediately upstream of
the Rta translation initiation codon. This reporter plasmid
has previously been shown to be responsive to TPA or
sodium butyrate and was previously validated as a tool
for studying transcriptional regulation of the Rta pro-
moter (Deng et al., 2000). The VSV-G expression plasmid
pHCMV-G (Yee et al., 1994) was a gift from Dr. Jane Burns
(University of California, San Diego).
Virus production and cell transfection methods
VSV-G-pseudotyped HIV virions were produced by
transfecting 293T cells with pNL4-3 or pMtat() proviral
DNA (10 g) together with pHCMV-G (2 g) in 10-cm2
dishes using calcium phosphate as previously described
(Varthakavi et al., 1999). Virus was harvested from super-
natants and p24 content quantified with a commercial kit
(DuPont NEN Life Science Products, Boston, MA). Infec-
tion of BC-3 cells was performed using 20 ng p24 per 1
106 cells. Transfection of 293 cells and BC-3 cells for
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reporter gene assays was performed using calcium
phosphate. Transfection of BC-3 cells was performed
using cationic liposome-mediated transfection employ-
ing liposomes made from dimethyl dioctadecyl ammo-
nium bromide, phosphatidyl serine, and phosphatidyl
ethanolamine prepared as described elsewhere (Rose et
al., 1991).
Northern blot analysis
BC-3 cells were subjected to treatment with 20 ng/ml
tetradecanoyl phorbol acetate (TPA) or to infection with
VSV-G-pseudotyped HIV-1NL4-3 (20 ng p24 per 1  10
6
cells). Cells were harvested at 0, 4, 8, 12, and 24 h
following treatment, and polyadenylated RNA was iso-
lated with the PolyATract system 1000 (Promega) using
the methods described by the manufacturer. The polyad-
enylated RNAs were concentrated by adding 1/10th vol 3
M sodium acetate followed by precipitation with 2-iso-
propanol. The concentration of mRNA in each prepara-
tion was evaluated using the poly(A) mRNA detection
system (Promega). Five hundred nanograms of each
RNA preparation was subjected to electrophoresis on a
1% formaldehyde-agarose gel and then transferred to a
nylon membrane (-Probe blotting membranes, Bio-Rad
Laboratories, Hercules, CA). RNA was crosslinked to the
membranes using ultraviolet light, and the membranes
were then baked for 2 h at 80°C. Following a 2-h prehy-
bridization step, hybridizations were performed in Hy-
brisol 1 solution (Intergen, Purchase, NY) using probes
specific for ORF 50, vIL-6, PAN, or GAPDH. The cDNA
probes were generated by reverse transcription from
purified BC-3 RNA using RT-PCR beads (Amersham
Pharmacia Biotech, Piscataway, NJ). The primer pairs
used for generating the probes were as follows: ORF 50
forward primer 5-ATGCCAGAATCTTTAATT TTG-3; ORF
50 reverse primer, 5-GAGGGACTACTGTTGGCAACT G;
PAN forward primer, 5-GCATTGGATTCAATCTCCAG-
GCC; PAN reverse primer, 5-CATTGTTACACAACGCTT-
TCACC; vIL-6 forward primer, 5-ATGTGCTGGTTCAAGT-
TGTGG; V-IL-6 reverse primer, 5-TTACTTATCGTG-
GACGTCAGG. The GAPDH probe was purchased from
Clontech (catalog No. 9805-1). The probes were labeled
with 32P using the Rediprime II labeling kit (Amersham).
Following overnight hybridization, the membranes were
washed three times in decreasing strengths of SSC
buffer containing 0.1% SDS. The final wash was a high-
stringency wash performed at the hybridization temper-
ature to ensure complete removal of unbound probe.
Membranes were then exposed to Kodak Biomax-MS
film (Kodak, Rochester, NY).
Rta and HIV-LTR reporter assays
293 cells were grown in six-well plates to 40–50%
confluence and were transfected by the calcium phos-
phate transfection method with 2.5 g reporter DNA
(pRPLuc, pHIVLTRlacZ) and 2.5 g proviral or Tat expres-
sion vector DNA (pNL4-3, pMtat(), or pSV2tat72). BC-3
cells (5 106) were transfected in an identical manner by
lipofection. To control for transfection efficiency, trans-
fections also included 100 ng of a green fluorescent
protein (GFP) expression plasmid (pEGFP-N3, Clontech).
The total amount of DNA transfected in each well was
normalized to 10.1 g using empty vector plasmid DNA
(pCDNA 3.1, Invitrogen). Transfected cells were collected
at 48 h posttransfection, washed, and suspended in 200
l of firefly luciferase reporter lysis buffer (Promega).
After freeze-thawing, the lysates were clarified by cen-
trifugation. Twenty microliters of the clarified cell lysate
was placed in a well of a 96-well plate and 200 l
luciferase substrate added. Luminescence was detected
in a microplate luminescence counter (TopCount, Pack-
ard Instrument Co., Meriden, CT). GFP fluorescence was
quantified in a microplate fluorescence spectrophotom-
eter (BMG Lab Technologies, Durham, NC) using an
excitation filter of 450 nm and emission filter of 510 nm.
Results were expressed as average luminescence
counts from triplicate wells corrected for transfection
efficiency. A colorimetric -galactosidase assay was
also performed where indicated to quantitate Tat activity.
For this assay, cell lysates (50 l) were placed in a
96-well plate to which an equal volume of substrate
solution (1 M Na2HPO4, 1 M NaH2PO4, 1 M KCl, 14.3 M
-mercaptoethanol, 1 M MgSO4), and chloro-red--D-ga-
lactopyranoside was added to a final concentration of 16
mM. Kinetic readings were obtained over a period of 5
min in a microplate spectrophotometer at 590 nm wave-
length. Results were expressed as Vmax (OD590) and
represent an average of triplicate assays following cor-
rection for transfection efficiency by GFP fluorescence.
Immunoprecipitation and immunofluorescence
analysis
ORF 59 monoclonal antibody 11D1 was provided by
Dr. Bala Chandran (University of Kansas Medical Center,
Kansas City). This antibody was used to detect lytic
replication of KSHV by immunoprecipitation and by im-
munofluorescence detection of the ORF 59 gene product
following exposure of BC-3 cells, Tat protein, or other
indicated treatments. BC-3 cells (10  106) were trans-
fected with 10 g HIV proviral DNA or pSVtat72 together
with 5 g pHIVLTR-luc. Immunoprecipitation analysis
was performed by labeling BC-3 cells for 36–38 h post-
treatment with 250 Ci [35S]cysteine/methionine (ICN,
Irvine, CA) using methods described previously
(Varthakavi et al., 1999). Immunofluorescence analysis of
BC-3 cells was performed on cells harvested 48 h fol-
lowing treatment with Tat, soluble factor-containing su-
pernatants, or other treatments as indicated. Immunoflu-
orescence analysis of the ORF 59 gene product was
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performed using the 11D1 monoclonal antibody as pre-
viously described (Varthakavi et al., 1999).
Recombinant Tat protein and quantitation of Tat
activity
Recombinant full-length (86 amino acid) Tat protein
used in our experiments was expressed in and purified
from bacteria using expression plasmid ptatC6H-1 and
metal chelate chromatography under conditions as de-
scribed (Patki and Lederman, 1996). Purified Tat protein
was normalized for Tat activity assayed on a T cell line
incorporating a stably integrated, tat-deficient HIV provi-
ral DNA (CEMtat() cells). The Tat activity of the prepa-
rations (10 g/ml) resulted in an average of 15 ng/ml p24
released from CEMtat() cells as measured by commer-
cial p24 capture ELISA kit (DuPont). This activity repre-
sented greater than 3 log induction over baseline p24
release, verifying the biological activity of the prepara-
tion. BC-3 or CEMtat() cells were treated with purified
Tat protein at 10 g/ml in 1 ml of either serum free
medium or Opti-MEM/PBS containing protamine sulfate
at 100 g/ml. After 60 h of treatment, the supernatants
were examined for p24 concentrations by ELISA. Key
results obtained using this in-house protein preparation
were validated using recombinant Tat protein obtained
from Dr. John Brady through the NIH AIDS Research and
Reference Reagent Program.
Preparation of supernatants from HIV-infected BC-3
cells containing KSHV lytic activity
BC-3 cells were infected with 20 ng VSV-G-
pseudotyped HIV-1NL4-3 per 1  10
6 cells. Supernatants
were harvested 48 h postinfection, clarified by centrifu-
gation at 2000 g, and filtered through a 0.22-M filter
prior to freezing at 70°C. For production of virus-de-
pleted supernatants, filtered supernatants were sub-
jected to ultracentrifugation at 100,000 g for 3 h, and the
supernatants were removed from the viral pellet prior to
storage. Tat-depleted supernatants were produced by
incubating the filtered supernatants with 5 g/ml anti-Tat
monoclonal antibody NT3 2D1-1 (Dingwall et al., 1989)
(obtained through NIH AIDS Research and Reference
Reagent Program, from Dr. J. Karn) followed by removal
of the resulting immune complexes with Protein
A–Sepharose beads. Control supernatants were pre-
pared from MT-2 cells infected with an equal amount of
pseudotyped HIV-1NL4-3 and were harvested and stored in
an identical manner. Tat activity in each of the superna-
tants from these experiments was quantitated using the
CEMtat() cell line described above.
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